The oFM is introduced, a foundation model developed on a real-world oncology cohort of 1.67 million cancer patients that integrates clinical trajectories with DNA, RNA, and H&E pathology and achieves a three-fold higher pooled and scale-normalized treatment-benefit AUTOC than baseline features.
Abstract
Precision oncology necessitates a longitudinal model of patient state that captures cancer evolution and treatment over time, integrating multimodal observations. We introduce the oFM, a foundation model developed on a real-world oncology cohort of 1.67 million cancer patients that integrates clinical trajectories with DNA, RNA, and H&E pathology. Patient-level partitions were reserved for training, validation, and testing, with over one million patients used for training. The oFM encodes daily clinical and molecular episodes and, along with pathology images, integrates them over time to produce a patient state embedding. We evaluate frozen oFM embeddings against expert-curated clinical and molecular baseline features. In prognostic benchmarks, the oFM improved AUC for treatment response, progression-free survival, and overall survival (0.774 vs. 0.563 for overall survival). Across 11 comparative-treatment cohorts, the oFM embeddings achieved a three-fold higher pooled and scale-normalized treatment-benefit AUTOC than baseline features with improved benefit ranking in 9 of 11 cohorts, and provided stronger prognostic discrimination within both treatment arms. We also evaluated a mechanism discovery framework that interprets downstream models built on oFM embeddings by linking their predicted outcomes to clinically and biologically grounded mechanisms through an evidence-grounded temporal graph, enabling evaluation in clinical and drug-development applications.
Recent advances and emerging translational evidence for clinically oriented MML in glioblastoma is summarized, with particular emphasis on MRI-centered systems that integrate imaging with pathology, selected molecular measurements, and longitudinal clinical context.
Amin Zadeh-Shirazi, Bryan W. Day, Hui K. Gan et al.· Frontiers in Oncology· 0 citations
A multi-tier, explainable AI framework designed to risk-stratify patients and predict overall survival using clinical and genomic covariates is developed and demonstrates that explainable machine learning models can robustly predict survivability and highlight actionable features for oncology dashboards.
Accurate prediction of tumor recurrence in brain tumor patients following surgery is essential for optimizing adjuvant therapy, response assessment, and surveillance regimen. While MRI remains the gold standard for surveillance, integrating patient-specific clinical context may inform recurrence prediction. Traditional...
D. Tak, D. Sreedhar, H. Aerts et al.· medRxiv· 0 citations
MRI foundation models (FMs) have shown potential for improving performance of neuroimaging tasks, but their value specifically in Glioblastoma overall survival risk prediction remains unclear. In this study, we explored foundation model initialization for preoperative risk prediction using publicly available structur...
Rakesh Khanna, Fanyang Yu, Minkyu Park et al.· npj Precision Oncology· 0 citations
Oncoformer provides a framework for risk-informed cancer prediction and treatment stratification using routine clinical data and was independently validated against postoperative pathological endpoints and shown to converge on core cancer genomic pathways.
Fei Liu, Kai Wang, Hui Xu et al.· Cell· 2 citations
This review synthesizes key developments in ML for oncology, covering foundational algorithms alongside emerging approaches, and describes future directions, including federated learning, graph neural networks, longitudinal modeling, and integration of real-world and wearable data to support precision oncology.
Kanishk Yadav, Taneesha Gupta· Journal of the Egyptian Nati...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.